Healthcare · Biotechnology
Price
$3.11
Market Cap
$540,139
Employees
17
Beta
1.24
Avg Volume
31,220,650
CEO
James Foster
Business Description
Virax Biolabs Group Limited is a biotechnology firm that specializes in the sale, distribution, and promotion of diagnostic testing kits, medical technology, and personal protective equipment (PPE). Its offerings are designed to aid in the prophylaxis, identification, diagnosis, and management of risks associated with viral illnesses within the immunology sector. Under its ViraxClear brand, the company provides a range of diagnostic tools, including rapid antibody IgG/IgM assays, antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody assessments. Additionally, it supplies medical technology and PPE products, such as employee safety gear marketed under the ViraxCare brand, alongside infrared thermometers, pulse oximeters, face coverings, gloves, and other protective items. Virax Biolabs also distributes nebulizer devices and intelligent wearable technology engineered to remind staff about social distancing protocols. The company operates an e-commerce platform where its ViraxClear and ViraxCare product lines are available for purchase. Its diverse clientele encompasses medical facilities, pharmacies, research laboratories, healthcare systems, corporate entities, individual purchasers, and both public and private organizations. With operations spanning Europe, South America, the Asia Pacific region, Sub-Saharan Africa, and other international markets, the company maintains a global presence. Established in 2021 and headquartered in London, United Kingdom, the entity was formerly known as Virax Biolabs (Cayman) Limited, officially adopting its current name in September 2021.
Business History
Price Overview
Last updated: Jun 27, 2026 10:09am (just now)$3.11
-0.27 (-7.85%)
Day Range
$2.75 – $4.75
52-Week Range
$2.50 – $28.50
50-Day MA
$4.39
200-Day MA
$8.39
Volume
637,603.00
Analyst Price Targets
Low
$1.00
Consensus
$1.00
High
$1.00
(1 analysts)
Share Structure
Outstanding
173,678.00
Float
156,162.00
Free Float
89.9%
High free float
— 89.9% of shares trade freely, ~10.1% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (0.2M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-1.59
Stock Price: $3.11
EPS (Diluted): -1.96
EPS (Diluted): -1.96
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.62
Stock Price: $3.11
Total Equity: $5.70M
Shares: 3,103,552
Total Equity: $5.70M
Shares: 3,103,552
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.41
Market Cap: $540,139
Total Debt: $32,468
Cash: $4.23M
EBITDA: -$5.80M
Total Debt: $32,468
Cash: $4.23M
EBITDA: -$5.80M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$-321,246
Market Cap: $540,139
Total Debt: $32,468
Cash: $4.23M
Total Debt: $32,468
Cash: $4.23M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
557.68
Stock Price: $3.11
Revenue: $6,331
Shares: 3,103,552
Revenue: $6,331
Shares: 3,103,552
EV/Sales (Total value vs revenue — works when P/E can't)
API-50.74
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
-838.2%
Gross Profit: -$53,067
Revenue: $6,331
Revenue: $6,331
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-97,344.8%
Operating Income: -$6.16M
Revenue: $6,331
Revenue: $6,331
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-95,739.2%
Net Income: -$6.06M
Revenue: $6,331
Revenue: $6,331
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-102.5%
Net Income: -$6.06M
Total Equity: $5.70M
Total Equity: $5.70M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-99.8%
Operating Income: -$6.16M
Tax Rate: 2.2%
Equity: $5.70M
Total Debt: $32,468
Cash: $4.23M
Tax Rate: 2.2%
Equity: $5.70M
Total Debt: $32,468
Cash: $4.23M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
7.27
Current Assets: $4.89M
Current Liabilities: $673,207
Current Liabilities: $673,207
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $32,468
Long-Term Debt: $0.00
Total Debt: $32,468
Total Equity: $5.70M
Long-Term Debt: $0.00
Total Debt: $32,468
Total Equity: $5.70M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.00
Revenue: $6,331
Shares: 3,103,552
Shares: 3,103,552
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.84
Total Equity: $5.70M
Shares: 3,103,552
Shares: 3,103,552
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.67
Operating CF: -$4.56M
CapEx: -$603,890
Shares: 3,103,552
CapEx: -$603,890
Shares: 3,103,552
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.11
Stock Price: $3.11
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$6.06M
Net Income: -$6.06M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VRAX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 12:00pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $123,820 | $0 | $8,561 | $156,419 | $6,331 |
| Cost of Revenue | $133,254 | $0 | $9,926 | $105,829 | $59,398 |
| Gross Profit | $-9,434 | $0 | $-1,365 | $50,590 | $-53,067 |
| Operating Expenses | $635,104 | $1.7M | $5.7M | $6.5M | $6.1M |
| Operating Income | $-644,540 | -$1.7M | -$5.7M | -$6.5M | -$6.2M |
| Net Income | $-650,984 | -$1.7M | -$5.5M | -$6.7M | -$6.1M |
| EBITDA | $-644,272 | $-750 | -$5.4M | -$6.6M | -$5.8M |
| EPS | $-0.57 | $-1.50 | $-5.13 | $-3.36 | $-1.96 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 12:00pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $17,621 | $21,756 | $9.4M | $3.6M | $4.2M |
| Total Current Assets | $39,621 | $48,706 | $9.6M | $4.4M | $4.9M |
| Total Assets | $94,118 | $48,706 | $9.8M | $5.5M | $6.4M |
| Current Liabilities | $871,435 | $1.2M | $908,401 | $168,849 | $673,207 |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $871,435 | $1.2M | $908,401 | $345,194 | $964,750 |
| Total Equity | $-596,185 | $-974,578 | $9.1M | $5.4M | $5.7M |
| Retained Earnings | -$4.6M | -$6.3M | -$11.8M | -$18.5M | -$24.6M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 12:00pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-590,186 | $-809,069 | -$4.2M | -$6.2M | -$4.6M |
| Capital Expenditure | $0 | $0 | $-178,403 | -$1.2M | $-603,890 |
| Free Cash Flow | $-590,186 | $-809,069 | -$4.4M | -$7.4M | -$5.2M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-4,988 | $4,135 | $9.3M | -$5.8M | $639,700 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 3:13am (6h ago)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$1.4M $1.4M – $1.4M
|
$25,000 $25,000 – $25,000
|
$40,000 $40,000 – $40,000
|
$4,000 $4,000 – $4,000
|
| EBITDA |
$-840,000 $-840,000 – $-840,000
|
$-15,000 $-15,000 – $-15,000
|
$-24,000 $-24,000 – $-24,000
|
$-2,400 $-2,400 – $-2,400
|
| Net Income |
$-235,871 $-235,871 – $-235,871
|
$-183,731 $-183,731 – $-183,731
|
$-49,657 $-49,657 – $-49,657
|
$-29,794 $-29,794 – $-29,794
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 12:00pm (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -100.0% | — | +1,727.1% | -96.0% |
| Gross Profit Growth | +100.0% | — | +3,806.2% | -204.9% |
| Operating Income Growth | -169.0% | -230.7% | -13.3% | +5.1% |
| Net Income Growth | -162.5% | -219.4% | -23.4% | +10.0% |
| EBITDA Growth | +99.9% | -725,538.8% | -21.4% | +12.2% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-18 | HAIGHT NELSON M | 2,000.00 | $15.40 | $30,800 | |
| 2026-03-18 | HAIGHT NELSON M | 10,000.00 | $6.00 | $60,000 | |
| 2026-03-18 | HAIGHT NELSON M | 10,000.00 | $0.68 | $6,800 | |
| 2026-03-18 | HAIGHT NELSON M | 10,000.00 | $0.88 | $8,800 | |
| 2026-03-18 | McCracken Nigel William | 20,000.00 | $3.60 | $72,000 | |
| 2026-03-18 | McCracken Nigel William | 50,000.00 | $0.68 | $34,000 | |
| 2026-03-18 | McCracken Nigel William | 29,416.00 | $0.88 | $25,886 | |
| 2026-03-18 | Foster James Alexander Cunliffe | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Foster James Alexander Cunliffe | 37,250.00 | $50.00 | $1.9M | |
| 2026-03-18 | Foster James Alexander Cunliffe | 40,000.00 | $6.00 | $240,000 | |
| 2026-03-18 | Foster James Alexander Cunliffe | 50,000.00 | $0.68 | $34,000 | |
| 2026-03-18 | Foster James Alexander Cunliffe | 31,975.00 | $0.88 | $28,138 | |
| 2026-03-18 | Norton Evan Michael | 10,000.00 | $6.00 | $60,000 | |
| 2026-03-18 | Norton Evan Michael | 10,000.00 | $0.68 | $6,800 | |
| 2026-03-18 | Norton Evan Michael | 10,000.00 | $0.88 | $8,800 | |
| 2026-03-18 | Davis Jason | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Miller Iain David | 0.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VRAX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for VRAX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30